Lunaphore raises CHF2m Series C2 funding led by Swiss Entrepreneurs Fund

– SWITZERLAND, Lausanne –  Lunaphore Technologies SA, a Swiss life-sciences company developing innovative next-generation equipment for cancer research and tissue diagnostics, today announced the second closing of its Series C round totaling CHF 25M.

The CHF 2M Series C2 financing was provided by the Swiss Entrepreneurs Fund, who invested a total of CHF 5M in the company. The fund is linked to the Swiss Entrepreneurs Foundation, whose main focus is to invest in Swiss start-ups and SMEs in the growth phase (internationalization) with the goal of bridging the financing gap in Swiss innovation.

Didier Denat, Member of the Decision Committee for direct investments of the Swiss Entrepreneurs Fund and Head of Corporate Banking at Credit Suisse (Switzerland) Ltd. said: “With its outstanding management team and technological USPs, Lunaphore is able to show significant market traction, combined with a high degree of customer satisfaction. We are fully convinced in both the business model and strategy of Lunaphore and we are happy to contribute in taking the company to the next level.”

The proceeds of the overall CHF 25M Series C closing, with the first closing announced on February 6, 2020 and led by the Japanese strategic investor PHC Holdings Corporation (PHCHD), will be dedicated to market and product expansion, including a US market entry, the ramp-up of activities in Europe and the development of next-generation of instruments.

“We are very happy to add the Swiss Entrepreneurs Fund, which focuses on high-growth companies with global ambitions, to our investors’ base. Together with the strategic investment from PHCHD that we recently closed, Lunaphore is now backed by very strong institutions to achieve its vision.”

About Lunaphore

Lunaphore Technologies S.A. is a Swiss company developing next-generation tissue autostainers. The award-winning technology based on microfluidics is called FFeX (Fast Fluidic Exchange). It aims to perform assays much faster than standard techniques and has demonstrated good results in tests with cancer patient samples. Lunaphore was founded in 2014 with the vision of bringing –omics like approaches to tissue analytics and has been recognized as one of the most innovative companies nationally and internationally.

For more information:

About Swiss Entrepreneurs Fund

Launched jointly by the Swiss Entrepreneurs Foundation, Swiss Mobiliar, Credit Suisse and UBS, the Swiss Entrepreneurs Fund invests in Swiss start-ups and growth-stage innovative SMEs that already have products on the market and an established client base. The fund has a unique connection to the Swiss Entrepreneurs Foundation, which was launched by Swiss Mobiliar, Credit Suisse, UBS, Swisscom, the Gebert Rüf Foundation and Wenger & Vieli. The fund invests directly and through third-party funds in companies that have their headquarters or a significant share of their value-added in Switzerland. Credit Suisse is responsible for direct investments, while UBS is in charge for selecting the fund investments.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.